Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.55 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.53 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL8486919 | 0.94 | HRH3 (0.57) | HRH3HIF1AEPAS1SMN1; SMN2LMNA | |
| SCHEMBL19534355 | 0.91 | HRH3 (0.54) | HRH3HIF1AEPAS1 | |
| SCHEMBL13266930 | 0.89 | HPGD (0.57) | HRH3HIF1AEPAS1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27990811 | 0.87 | HRH3 (0.52) | HRH3SMN1; SMN2LMNAALDH1A1MAPK1 | |
| SCHEMBL13984650 | 0.86 | HRH3 (0.56) | HRH3HIF1AEPAS1SMN1; SMN2LMNA | |
| SCHEMBL20432799 | 0.85 | HRH3 (0.48) | HRH3HIF1AEPAS1SMN1; SMN2LMNA | |
| SCHEMBL15467001 | 0.84 | HRH3 (0.87) | HRH3HIF1AEPAS1SMN1; SMN2LMNA | |
| SCHEMBL14058774 | 0.84 | HRH3 (0.67) | HRH3HIF1AEPAS1SMN1; SMN2LMNA | |
| SCHEMBL470384 | 0.83 | HRH3 (0.59) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL3694234 | 0.83 | HRH3 (0.65) | HRH3SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | claimed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | claimed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | claimed |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEIGENE, LTD. (KY) | 2025-04-22 | — | — | US | disclosed |
| CN-113454086-B | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240398783-A1 | Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof | GISMO THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4398902-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF AMYLOID PEPTIDE INTERACTIONS WITH GLYCOSAMINOGLYCANS, METHODS OF TREATMENT, AND USE THEREOF | Gismo Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-117999075-A | Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interaction with glycosaminoglycans, methods of treatment, and uses thereof | 吉斯莫治疗股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| US-11807620-B2 | Quinazolinone compounds and related compounds | Plexium, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807620-B2 | Quinazolinone compounds and related compounds | Plexium, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-1998048804-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5807891-A | RETROVIRUSES | NOVARTIS AG (CH) | 1998-09-15 | — | — | US | disclosed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5663200-A | CARBAMOYL PEPTIDE DERIVATIVES AS VIRICIDES | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0767798-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |
| WO-1996000235-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1996-01-04 | — | — | WO | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398783-A1 | Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof | PRNP, GBA1, GBA3 | HRH3 274/4885HIF1A 3381/4885EPAS1 1393/4885 |
| US-11807620-B2 | Quinazolinone compounds and related compounds | NQO2, COQ8A, PARK7 | HRH3 2946/4885HIF1A 3145/4885EPAS1 658/4885 |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR1, TLR3 | HRH3 324/4885HIF1A 4153/4885EPAS1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.